A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
The study will assess the efficacy and safety of 2 dose regimens of pegozafermin for the treatment of liver fibrosis stage 2 or 3 in adult participants with MASH (previously known as nonalcoholic stea...
Digoxin In NASH (CODIN)
Nonalcoholic steatohepatitis (NASH) is a severe subtype of nonalcoholic fatty liver disease (NAFLD) which affects 1 in 3 Americans. The mainstay of treatment for NASH, which was recently renamed metab...
Fibrosis Lessens After Metabolic Surgery
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), a major global public health concern, is commonly associated with obesity...
Quantifying Hepatic Mitochondrial Fluxes in Humans
In this study the investigators will quantitate hepatic mitochondrial fluxes in T2D patients with NAFL and NASH before and after 16-weeks treatment with the insulin sensitizer pioglitazone...
MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
The design of the Phase 2 clinical trial includes the following elements: * Multi-center, two-arm, randomized, double-blind, placebo-controlled trial to evaluate MN-001 (tipelukast) vs. placebo in ap...
Top Cities for Non-Alcoholic Fatty Liver Disease Clinical Trials
Non-Alcoholic Fatty Liver Disease clinical trials are recruiting across 24 cities. Here are the cities with the most active studies:
About Non-Alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD/MASLD) is a condition where excess fat builds up in the liver without significant alcohol consumption. It is the most common liver disease in Western countries. Management includes weight loss, exercise, and treatment of associated metabolic conditions.
Clinical trials are advancing new treatments for non-alcoholic fatty liver disease. Currently, 5 studies are recruiting a combined 1,414 participants across the United States. Research is being conducted by 5 organizations including 89bio, Inc., Yale University, Ali Aminian and 2 others.
2026 Non-Alcoholic Fatty Liver Disease Research Landscape
As of March 2026, the non-alcoholic fatty liver disease clinical trial landscape includes 5 actively recruiting studies across 24 cities in the United States. These studies are collectively seeking 1,414 participants, with an average enrollment target of 283 per study.
Research is being led by 5 different organizations, including 89bio, Inc., Yale University, Ali Aminian, The University of Texas Health Science Center at San Antonio, MediciNova.
Geographically, non-alcoholic fatty liver disease trials are most concentrated in New Haven, Connecticut (2 trials); San Antonio, Texas (2 trials); Birmingham, Alabama (1 trial); Chandler, Arizona (1 trial); Flagstaff, Arizona (1 trial) and 7 other cities.
Featured Non-Alcoholic Fatty Liver Disease Studies
Highlighted recruiting studies for non-alcoholic fatty liver disease, selected by enrollment size and research scope.
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
The study will assess the efficacy and safety of 2 dose regimens of pegozafermin for the treatment of liver fibrosis stage 2 or 3 in adult participants with MASH (previously known as nonalcoholic steatohepatitis \[NASH\]).
Digoxin In NASH (CODIN)
Nonalcoholic steatohepatitis (NASH) is a severe subtype of nonalcoholic fatty liver disease (NAFLD) which affects 1 in 3 Americans. The mainstay of treatment for NASH, which was recently renamed metabolic associated steatohepatitis (MASH), involves lifestyle interventions to promote weight loss and to treat comorbidities such as hypertension, hyperlipidemia, and diabetes mellitus. There is thus, a...
Fibrosis Lessens After Metabolic Surgery
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), a major global public health concern, is commonly associated with obesity, diabetes, and dyslipidemia. MASLD is currently the most common cause of chronic liver disease affecting about 80% of people with obesity, ranging from simple fat deposits in the liver to Metabolic D...
Frequently Asked Questions About Non-Alcoholic Fatty Liver Disease Clinical Trials
Are there non-alcoholic fatty liver disease clinical trials near me?
Yes, there are 5 non-alcoholic fatty liver disease clinical trials currently recruiting across 24+ cities in the United States, including New Haven, Connecticut; San Antonio, Texas; Birmingham, Alabama. Browse the studies above to find one at a location convenient for you.
How do I join a non-alcoholic fatty liver disease clinical trial?
To join a non-alcoholic fatty liver disease clinical trial: 1) Browse the available studies on this page, 2) Click on a study that interests you, 3) Check the study locations to find a site near you, 4) Review the eligibility criteria, and 5) Contact the study site or complete the eligibility form. The process is free and you can withdraw at any time.
Are non-alcoholic fatty liver disease clinical trials free?
Yes, participation in non-alcoholic fatty liver disease clinical trials is free. Study-related treatments, medical tests, and doctor visits are provided at no cost to participants. Many studies also offer compensation for your time and travel expenses.
What types of non-alcoholic fatty liver disease treatments are being studied?
Current non-alcoholic fatty liver disease clinical trials are testing a range of approaches. These include new drugs, combination therapies, medical devices, and other interventions sponsored by 5 research organizations.
Is it safe to participate in non-alcoholic fatty liver disease clinical trials?
Clinical trials are carefully regulated by the FDA and institutional review boards (IRBs). All trials must follow strict safety protocols, and participants receive close medical monitoring throughout the study. You can withdraw from a trial at any time without penalty.
Data updated March 1, 2026 from ClinicalTrials.gov
About This Data
Clinical trial information on this page is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health (NIH) and National Library of Medicine (NLM). Study data is refreshed every hour to ensure accuracy.
Medical Disclaimer: The information provided on this page is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making decisions about clinical trial participation or changes to your treatment plan.
Page reviewed by the HelloStudys Research Team · Last updated March 1, 2026 · Data from ClinicalTrials.gov